Takeda Closes Sales of 16 Non-Core Meds to Germany’s Cheplapharm

January 6, 2021
Takeda Pharmaceutical said on January 5 that it has completed the sale of non-core prescription medicines sold in Europe to German drug maker Cheplapharm for US$562 million, wrapping up a deal first announced in September last year. The divested products...read more